Company offers stock at $11.90 per share through Roth Capital Partners
By Devika Patel
Knoxville, Tenn., July 11 – Tonix Pharmaceuticals Holding Corp. said it plans a $7.82 million registered direct offering of stock.
The company will sell 657,000 common shares. The purchase price of $11.90 per share reflects a 4.95% discount to the $12.52 closing share price on July 10.
Settlement is expected July 16.
Roth Capital Partners is the agent.
Proceeds will be used for development of TNX-102 SL, clinical trials, development of other programs, working capital, general corporate purposes and possible acquisitions.
Tonix is a specialty pharmaceutical company based in Zurich.
| Issuer: | Tonix Pharmaceuticals Holding Corp.
|
| Issue: | Common stock
|
| Amount: | $7,818,300
|
| Shares: | 657,000
|
| Price: | $11.90
|
| Warrants: | No
|
| Agents: | Roth Capital Partners
|
| Pricing date: | July 11
|
| Settlement date: | July 16
|
| Stock symbol: | Nasdaq: TNXP
|
| Stock price: | $12.52 at close July 10
|
| Market capitalization: | $118.16 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
